Last reviewed · How we verify
Placebo to ozanimod
Ozanimod is a selective sphingosine-1-phosphate (S1P) receptor modulator that reduces lymphocyte egress from lymphoid tissues, decreasing circulating lymphocytes and inflammatory cell infiltration into affected tissues.
Ozanimod is a selective sphingosine-1-phosphate (S1P) receptor modulator that reduces lymphocyte egress from lymphoid tissues, decreasing circulating lymphocytes and inflammatory cell infiltration into affected tissues. Used for Ulcerative colitis, Crohn's disease.
At a glance
| Generic name | Placebo to ozanimod |
|---|---|
| Sponsor | Celgene |
| Drug class | Sphingosine-1-phosphate (S1P) receptor modulator |
| Target | S1P1 and S1P5 receptors |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
Ozanimod selectively binds to S1P1 and S1P5 receptors on lymphocytes and other immune cells, preventing their migration from lymph nodes into peripheral circulation. This reduces the number of pathogenic lymphocytes available to infiltrate inflamed tissues. The drug is particularly effective in autoimmune and inflammatory conditions where lymphocyte trafficking drives disease pathology.
Approved indications
- Ulcerative colitis
- Crohn's disease
Common side effects
- Headache
- Diarrhea
- Nausea
- Upper respiratory tract infection
- Bradycardia (dose-dependent)
Key clinical trials
- Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis (PHASE3)
- Induction Study #1 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease (PHASE3)
- To Evaluate Efficacy and Long-term Safety of Ozanimod in Japanese Subjects With Moderately to Severely Active Ulcerative Colitis (PHASE3)
- A Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohn's Disease (PHASE3)
- A Study to Evaluate Efficacy and Long-term Safety of Oral Ozanimod in Chinese Participants With Moderately to Severely Active Ulcerative Colitis (UC) (PHASE3)
- Induction Study #2 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease (PHASE3)
- Study to Evaluate the Pressor Effect of Oral Tyramine During Ozanimod Treatment in Healthy Adult Participants (PHASE1)
- Safety and Efficacy Trial of RPC1063 for Moderate to Severe Ulcerative Colitis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo to ozanimod CI brief — competitive landscape report
- Placebo to ozanimod updates RSS · CI watch RSS
- Celgene portfolio CI